Comparative cardiovascular safety of dementia medications: A cross-national study

Journal of the American Geriatrics Society

Volumn 60, Issue 12, 2012, Pages 2283-2289

  Fosbøl, Emil L ^a   Peterson, Eric D ^a,b   Holm, Ellen ^c   Gislason, Gunnar H ^d   Zhang, Yinghong ^a   Curtis, Lesley H ^a,b   Kober, Lars ^e   Iwata, Isao ^a,b   Torp Pedersen, Christian ^d   Setoguchi, Soko ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROSKILDE HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e Mental Health Center Glostrup   (Denmark)

Author keywords

cardiovascular system; cholinesterase inhibitors; dementia; Denmark; drug toxicity; Medicare; memantine; United States

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DENMARK; DRUG SAFETY; FAINTNESS; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; RETROSPECTIVE STUDY; SIDE EFFECT; UNITED STATES;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DEMENTIA; DENMARK; FEMALE; HEART FAILURE; HUMANS; INDANS; MALE; MEDICARE; MEMANTINE; MYOCARDIAL INFARCTION; NOOTROPIC AGENTS; PIPERIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; UNITED STATES;

EID: 84871002811     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2012.04241.x     Document Type: Article

References (30)

1. Birks JS, Melzer D, Beppu H,. Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst Rev 2000; 4: CD001190.
2. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-2330.
3. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-620.
4. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-397.
5. McShane R, Areosa Sastre A, Minakaran N,. Memantine for dementia. Cochrane Database Syst Rev 2006; 2: CD003154.
6. Martorana A, Esposito Z, Koch G,. Beyond the cholinergic hypothesis: Do current drugs work in Alzheimer's disease? CNS Neurosci Ther 2010; 16: 235-245.
7. McCain KR, Sawyer TS, Spiller HA,. Evaluation of centrally acting cholinesterase inhibitor exposures in adults. Ann Pharmacother 2007; 41: 1632-1637.
8. Haibara AS, Colombari E, Chianca DA Jr, et al. NMDA receptors in NTS are involved in bradycardic but not in pressor response of chemoreflex. Am J Physiol 1995; 269: H1421-H1427.
9. Huang CF, Su MJ,. Positive inotropic action of NMDA receptor antagonist (+)-MK801 in rat heart. J Biomed Sci 1999; 6: 387-398.
10. Martindale: The Complete Drug Reference, 35th Ed. London: Pharmaceutical Press, 2007.
11. van Eijk MM, Roes KC, Honing ML, et al. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: A multicentre, double-blind, placebo-controlled randomised trial. Lancet 2010; 376: 1829-1837.
12. Morganroth J, Graham S, Hartman R, et al. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42: 558-568.
13. Ballard C, Lane R, Barone P, et al. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 2006; 60: 639-645.
14. Sato K, Urbano R, Yu C, et al. The effect of donepezil treatment on cardiovascular mortality. Clin Pharmacol Ther 2010; 88: 335-338.
15. Gallini A, Sommet A, Montastruc JL,. Does memantine induce bradycardia? A study in the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf 2008; 17: 877-881.
16. van Laar T, De Deyn PP, Aarsland D, et al. Effects of cholinesterase inhibitors in Parkinson's disease dementia: A review of clinical data. CNS Neurosci Ther 2011; 17: 428-441.
17. Fosbol EL, Gislason GH, Jacobsen S, et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: A nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 2008; 17: 822-833.
18. Kumler T, Gislason GH, Kirk V, et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 2008; 10: 658-660.
19. Madsen M, Davidsen M, Rasmussen S, et al. The validity of the diagnosis of acute myocardial infarction in routine statistics: A comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003; 56: 124-130.
20. Kiyota Y, Schneeweiss S, Glynn RJ, et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: Estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004; 148: 99-104.
21. Quach S, Blais C, Quan H,. Administrative data have high variation in validity for recording heart failure. Can J Cardiol 2010; 26: 306-312.
22. Movahed MR, Hashemzadeh M, Jamal MM,. Increased prevalence of third-degree atrioventricular block in patients with type II diabetes mellitus. Chest 2005; 128: 2611-2614.
23. Suzuki T, Matsunaga N, Kohsaka S,. Diagnostic patterns in the evaluation of patients hospitalized with syncope. Pacing Clin Electrophysiol 2006; 29: 1240-1244.
24. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
25. Schneider LS, Dagerman KS, Insel P,. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-1943.
26. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study. Arch Intern Med 2009; 169: 867-873.
27. Rowland JP, Rigby J, Harper AC, et al. Cardiovascular monitoring with acetylcholinesterase inhibitors: A clinical protocol. Adv Psychiatr Treat 2007; 13: 178-184.
28. Lockhart IA, Mitchell SA, Kelly S,. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: Systematic review of the 'real-world' evidence. Dement Geriatr Cogn Disord 2009; 28: 389-403.
29. Sonkusare SK, Kaul CL, Ramarao P,. Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res 2005; 51: 1-17.
30. Lin PJ, Kaufer DI, Maciejewski ML, et al. An examination of Alzheimer's disease case definitions using Medicare claims and survey data. Alzheimers Dement 2010; 6: 334-341.